LTGO news

Latest 1 stories · newest Nov 5, 2026

LTGO

Latigo Biotherapeutics Reports Q3 Financials and Pipeline Progress

The company reported $401 million in cash and expects to initiate Phase 3 trials for onzotrigine, with topline results anticipated in 2027, demonstrating strong financial footing to advance non-opioid pain candidates.

Earnings Nov 5, 2026 sentiment +0.50 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same LTGO feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/LTGO/newsSTART FREE